Kahn Swick & Foti, LLC has launched an investigation into Sarepta Therapeutics following multiple patient deaths from acute liver failure linked to its gene therapy Elevidys, used to treat Duchenne muscular dystrophy. Despite Sarepta's initial assurances about the therapy's safety, three patients died between March and June 2025, leading to a securities class action lawsuit against the company and some executives for allegedly withholding material risk information. The investigation aims to determine if Sarepta's leadership breached fiduciary duties or violated laws. Investors with information or concerns are encouraged to contact the law firm for potential legal action.
A class action lawsuit has been filed against Papa John's International by investors who bought stock between August 7, 2025, and August 5, 2026. The suit alleges the company misled investors about its business prospects, including sales, dividends, ...
Tesla introduced the Cybercab on September 4, 2026, just six weeks after announcing it would not pursue volume production of the vehicle this year. This launch signals Tesla's continued interest in the Cybercab despite scaling back mass production pl...
Bitcoin fell sharply to $78,442 on August 28, 2026, after Federal Reserve Chair Kevin Warsh dismissed recent soft inflation data and ended the Fed's forward guidance, causing markets to price in higher interest rates for longer. This hawkish stance i...
Innovative Industrial Properties (IIPR) provides a high dividend yield of 13.4%, supported by a conservative balance sheet with low leverage (1.7x debt/EBITDA) and favorable regulatory changes in the cannabis sector. Despite tenant concentration risk...
Solana activated a rent reduction on September 3rd, lowering on-chain account storage costs by about 90%. This change reduces the Lamports-per-byte requirement, allowing existing accounts to withdraw surplus SOL without closing. Approximately 3.08 mi...
